Shanghai, China — [June 27, 2025] — Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter “Xianju Pharmaceutical”), a major Chinese manufacturer of steroid hormones, attended the CPHI & PMEC China exhibition held at the Shanghai New International Expo Center from June 24 to 26, 2025, as scheduled.
As Asia’s most influential pharmaceutical industry event, CPHI brings together tens of thousands of professional attendees and renowned companies from over 100 countries and regions worldwide, providing an excellent platform for pharmaceutical professionals to exchange ideas, collaborate, and gain insights into industry trends.
For many years, Xianju Pharmaceutical has consistently leveraged the CPHI international platform to deepen its global business footprint. Starting in 2024, building upon its existing Active Pharmaceutical Ingredients (API) business, the company officially introduced its “finished dosage forms” segment to the exhibition. At the 2025 exhibition, the company showcased its advanced production technologies, rigorous quality control systems, and robust supply chain capabilities through professional presentations. Leveraging the advantages of production lines that have passed the U.S. Food and Drug Administration (FDA)’s stringent inspections and consistent adherence to international GMP standards, the company’s comprehensive strength across the entire industrial chain has garnered widespread recognition from global industry peers.
As a leading global upstream manufacturer of active pharmaceutical ingredients (APIs) for contraceptive products, Xianju Pharmaceutical also highlighted the synergistic advantages of its four core production bases during the event: the finished dosage form facility, the API facility, the Taizhou Xianju facility, and the NEWCHEM plant in Italy. These four bases form a fully controllable global production system that not only ensures the consistent quality of both APIs and finished products but also provides robust support for the company’s overseas finished dosage form export business, facilitating the efficient entry of products into global markets such as the EU and North America.
The exhibition served as a significant opportunity for Xianju Pharmaceutical to deepen international friendships and business cooperation. During the exhibition, Xianju Pharmaceutical’s professional team engaged in in-depth face-to-face discussions with numerous overseas clients and international partners, providing detailed introductions to the company’s international certifications and diversified cooperation models. Notably, during the 2025 exhibition negotiations, the team achieved significant results in exchanges with several foreign clients. Both parties reached numerous consensus points during business discussions, laying a solid foundation for further expanding the global market footprint and accelerating the overseas expansion of finished dosage forms.
In addition to business negotiations, the company’s team actively participated in high-level conferences and forums held during the exhibition, focusing on core topics such as updates to international pharmaceutical regulations and global pharmaceutical market trends. Through these exchanges, the team gained deep insights into the latest industry developments and regulatory requirements, providing valuable references for the company’s future international registration and overseas market expansion strategies.
A representative from Xianju Pharmaceutical stated: “As a regular exhibitor at CPHI, we have always regarded this event as a vital window for integrating into the global pharmaceutical industry. Since we began showcasing our finished dosage form business at the exhibition in 2024, our full-industry-chain global expansion strategy has received a positive response from the market. At this year’s exhibition, we were able to engage in in-depth discussions with numerous international partners and overseas clients and achieve fruitful results, which fills us with confidence for the future. “Moving forward, Xianju Pharmaceutical will continue to align with international standards, fully leverage the advantages of our integrated full-industry-chain operations and global production footprint, provide higher-quality pharmaceutical solutions to global clients, and contribute to the development of the global pharmaceutical industry.”
